Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations

ABSTRACT RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor combinations have demonstrated improved efficacy, likely through superior suppression of MAPK signaling. The first identified mechanisms of acquired resistance to these combinations all promote MAPK reactivation, underscoring the MAPK pathway as a critical target in BRAF-mutant CRC.

• Publication year

  2015

• Venue

  Molecular & Cellular Oncology

• Publication date

  2015-05-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/23723556.2015.1048405PMID 27308562PMCID 4845183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

  2015cited by this paper
• Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.

  2014cited by this paper
• Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

  2014cited by this paper
• EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

  2012cited by this paper
• Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

  2012cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

  2010cited by this paper
• BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

  2010cited by this paper
• KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

  2009cited by this paper
• Colorectal cancer (CRC)

  2009cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper

• BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer

  2023cites this paper
• Identification and characterization of a first-generation inhibitor of claudin-1 in colon cancer progression and metastasis.

  2023cites this paper
• BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells

  2021cites this paper
• Epigenetic modification and BRAF gene mutation in thyroid carcinoma

  2021cites this paper
• Immunotherapy for the treatment of colorectal cancer

  2021cites this paper
• Comprehensive analysis of expression profiles of long non-coding RNAs with associated ceRNA network involved in gastric cancer progression

  2019cites this paper
• CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition

  2019cites this paper
• Targeting Receptor Kinases in Colorectal Cancer

  2019cites this paper
• Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic RAS and BRAF variants

  2019cites this paper
• Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.

  2018cites this paper
• Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

  2017cites this paper
• Primary and acquired resistance to biologic therapies in gastrointestinal cancers.

  2017cites this paper
• The role of ERK5 signaling in colorectal cancer

  2016cites this paper